Infant Botulism TREATMENT AND PREVENTION PROGRAM
Please click on photos above for more information about how to obtain BabyBIG®, consultation for suspected infant botulism, and laboratory testing in California.
Also visit our infant botulism main page for in-depth information.
What is infant botulism? Infant botulism is an orphan ("rare") disease that affects infants primarily under 1 year of age. First recognized in 1976, infant botulism occurs globally and is the most common form of human botulism in the United States.
BabyBIG®, Botulism Immune Globulin Intravenous (Human) (BIG-IV) is an orphan drug that consists of human-derived anti-botulism toxin antibodies that is approved by the U.S. Food and Drug Administration for the treatment of infant botulism type A and type B.
Physicians
- How to obtain clinical consultation and order BabyBIG®
-
Call IBTPP Clinical Consultant at 510-231-7600 (24/7/365)
-
Clinical Diagnosis
- Patient Management
- Laboratory Diagnosis
-
FAQs (PDF)
If your patient is older than 15 months, please see CDPH Botulism Information for Health Professionals for instructions on requesting antitoxin.
International Info
Other Languages
Parents
In-Depth Information
Contact us by phone, fax, or email:
Phone: Physicians with a suspected case of infant botulism may reach our program at (510) 231-7600 (24/7/365). However, if you are a parent with concerns or questions about suspected infant botulism, please contact your pediatrician.
Email: If you have non-urgent questions or comments, please email the program at: IBTPP@infantbotulism.org
Fax: (510) 231-7609
For more in-depth information, please visit our infant botulism main page.